Copyright
©The Author(s) 2018.
World J Gastroenterol. Feb 14, 2018; 24(6): 706-715
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.706
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.706
Figure 1 Administration of rVIPa inhibited the pathogenic effects and body weight loss caused by TNBS.
A: The experimental scheme of induction of colitis and administration of rVIPa; B: Body weight of rats between days 1-10. rVIPa: Recombinant expressed vasoactive intestinal peptide analogue; TNBS: Trinitrobenzene sulfonic.
- Citation: Xu CL, Guo Y, Qiao L, Ma L, Cheng YY. Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats. World J Gastroenterol 2018; 24(6): 706-715
- URL: https://www.wjgnet.com/1007-9327/full/v24/i6/706.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i6.706